Drug Trial Radar · NCT06095089
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
355
Planned (sponsor's estimate)
Start
Nov 1, 2023
Primary completion
Jun 21, 2027
Study completion Jun 28, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or without apalutamide. Part 3 of this study evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with standard of care (SOC) lutetium Lu-177 vipivotide tetraxetan. Part 4 of this study further evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with JNJ-101556143 in participants with advanced prostate cancer.
Conditions
- Prostatic Neoplasms
Interventions
JNJ-78278343Drug
JNJ-78278343 will be administered.
JNJ-87189401Drug
JNJ-87189401 will be administered.
ApalutamideDrug
Apalutamide will be administered.
Lutetium Lu-177 Vipivotide TetraxetanDrug
Lutetium Lu-177 Vipivotide Tetraxetan will be administered as SOC treatment.
JNJ-101556143Drug
JNJ-101556143 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1, 2C, 3 and 4: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to 21 days after first combination dose of study drugs
- Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to 4 years 8 months
Locations
22 sites in 5 countries. Site status is shown where the registry gives one.
University of Colorado Anschutz Medical Campus
Aurora, Colorado · Recruiting
Emory University Winship Cancer Institute
Atlanta, Georgia · Recruiting
University Of Minnesota
Minneapolis, Minnesota · Recruiting
START New Jersey
East Brunswick, New Jersey · Recruiting
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
New York, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Atrium Health Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Oregon Health And Science University
Portland, Oregon · Recruiting
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, Pennsylvania · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
South Texas Accelerated Research Therapeutics, LLC (START)
San Antonio, Texas · Recruiting
Swedish Medical Center
Seattle, Washington · Recruiting
Greenslopes Private Hospital
Greenslopes, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Australia · Recruiting
Chongqing University Cancer Hospital
Chongqing, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China · Recruiting
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, China · Recruiting
Institut Bergonie
Bordeaux, France · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
The Cancer Institute Hospital of JFCR
Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.